The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824.


The Antibacterial Resistance Leadership Group (ARLG), with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, was created in June 2013. Its mission is to develop, prioritize, and implement a clinical research agenda that addresses the public health threat of antibacterial resistance. This article reports on the progress that the ARLG has made to date in fulfilling its mission. Since inception, the ARLG has received and reviewed >70 study proposals, initiated >30 studies, executed >300 agreements, included data from >7000 subjects, published >45 manuscripts, and provided opportunities for 26 mentees. Despite this substantial progress, there remains significant work to be accomplished. This article also describes the considerable challenges that lie ahead.

Keywords: antibacterial resistance; clinical trials.; diagnostics; network; stewardship.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Biomedical Research / organization & administration*
  • Drug Resistance, Bacterial*
  • Humans
  • Leadership
  • Research Report
  • Voluntary Health Agencies*


  • Anti-Bacterial Agents